
Business enterprise expenditure on pharmaceutical R&D and government budgets for health-related R&D, 2018 (or nearest year)
While no official data are yet available, a preliminary OECD analysis shows the COVID-19 pandemic has forced governments to invest tens of billions across the entire discovery and development chain, including late‑stage clinical trials for drugs and vaccines, moving beyond their traditional role in supporting early-stage research.